Femasys Inc 8-K, filed Sep 1, 2021
Femasys Inc (FEMY)
8-K
2021-09-01
For: 2021-09-01
View Original
Added on
April 06, 2026
About this 8-K
Femasys Inc filed this 8-K on September 1, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 1, 2021
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
,
,
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(770 ) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instructions A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 8.01 |
Other Events.
|
On September 1, 2021, Femasys Inc. (the “Company”) issued a press release announcing
the appointment of Edward Evantash, M.D. as its Chief Medical Officer. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
|
Press Release of Femasys Inc. dated September 1, 2021
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
|
Title: Chief Executive Officer
|
|
|
Date: September 1, 2021
|
||
Exhibit 99.1
Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer
-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys --
ATLANTA September 1, 2021 -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally
invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys, having
previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic, Inc., both medical technology companies focused on women’s healthcare. He will be responsible for providing leadership and direction for
Femasys’ pipeline of clinical development programs.
“We warmly welcome Edward and are fortunate to be able to draw on his clinical expertise in women’s health as we work to provide superior reproductive healthcare options to
women globally,” said Kathy Lee-Sepsick, president, CEO and founder of Femasys Inc. “Edward’s corporate experience leading clinical and medical affairs together with his clinical expertise serving as a chief of the division of Obstetrics and
Gynecology at Tufts, will prove invaluable as we continue to work with clinical trial sites and meet with the FDA to advance our late-stage candidates, FemaSeed™ and FemBloc®, into the next phases of development and prepare for
commercialization.”
Dr. Evantash commented, “I have witnessed the impact of the stagnant reproductive health treatment landscape and appreciate the desire for alternatives in permanent
contraception and infertility, which is why I am eager to contribute to the Femasys team. I look forward to the advancement of Femasys’ product candidates to fill these unmet needs, particularly as we execute the de novo clinical trial for FemaSeed and complete enrollment of the ongoing stage II FemBloc study.”
During his time at Alydia and Hologic, Dr. Evantash was responsible for applying his expertise in clinical study strategy and execution as well as key opinion leader
engagement, and in providing strategy and execution on clinical studies for FDA submissions. At Hologic, he developed and managed product lifecycle publication pipelines, identified customer knowledge gaps and created engaging programs to overcome
barriers to commercial success, and aligned with the healthcare economics team to recognize the changing reimbursement landscape and create a related strategy.
Before entering industry, Dr. Evantash served as chief of the division of general obstetrics and gynecology at Tufts Medical Center. In addition, he held faculty
appointments at Tufts University School of Medicine, Northeastern University and Harvard Medical School. He has published numerous peer-reviewed papers and book chapters in obstetrics and gynecology. Dr. Evantash served as chief resident at The Johns
Hopkins Hospital in the Department of Gynecology and Obstetrics when completing his residency training. He earned his M.D. from the University of Pennsylvania School of Medicine and graduated cum laude with a B.A. in biology from Brandeis University.
About FemaSeed™
FemaSeed is a directed sperm delivery product in development for infertility. FemaSeed is the first and only approach that allows localized directed delivery of sperm to
either or both fallopian tubes where conception occurs. FemaSeed is being evaluated in a prospective, multi-center pivotal trial, the “LOCAL” trial.
About FemBloc®
FemBloc is a first and only non-surgical, minimally invasive, in-office solution for permanent birth control in development. FemBloc uses a temporary degradable biopolymer
that is naturally excreted to close the fallopian tubes using the body’s own scar tissue. FemBloc is currently being evaluated in a prospective, multi-center stage II validation study.
About Femasys
Femasys Inc. is a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies.
Its two lead reproductive health product candidates include FemBloc® permanent birth control and FemaSeed™
localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in
the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical
products in the physician’s office setting.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be
identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “believe,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to
differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to
develop and advance our current product candidates and programs into, and successfully initiate and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive
results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties
described in the section titled "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2021, and other reports as filed with the SEC. Forward-looking statements contained in
this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com